

IN THE CLAIMS:

Please amend the claims as follows:

Cancel claims 72 and 73, without prejudice.

Amend claims 51, 55, 56, 60, 61, and 69-71, to read as follows:

1 ~~51.~~ (amended) A method for screening a molecule for the ability to modulate heat shock protein receptor activity comprising:

- B
SUB
F1
- (a) contacting heat shock receptor positive cells with the molecule; and
 - (b) comparing the level of heat shock protein receptor binding activity in the heat shock receptor positive cells contacted with the molecule to the amount of heat shock protein receptor binding activity in the heat shock receptor positive cells not so contacted,

wherein an increase or decrease in the amount of heat shock protein receptor binding activity in the contacted heat shock receptor positive cells relative to the amount of heat shock protein receptor binding activity in the heat shock receptor positive cells not so contacted indicates that the molecule has the ability to modulate heat shock protein receptor activity.

SUB
F2
B2 3
2 ~~55.~~ (amended) The method of claim ~~51~~ wherein the level of heat shock protein receptor binding activity is assayed by measuring the ability of the molecule to bind to the heat shock protein receptor positive cells.

~~56.~~ (amended) The method of claim ~~51~~ wherein the level of heat shock protein receptor binding activity is assayed by measuring the ability of the molecule to modulate the binding of a heat shock protein or a heat shock protein-peptide complex to the cells.

4 ~~60.~~ (amended) The method of claim ~~51~~ wherein the heat shock protein receptor binding activity is the ability to interact with a heat shock protein receptor antibody.

B
61. (amended) The method of claim ~~51~~ wherein the level of heat shock protein receptor binding activity is assayed by measuring antigen presentation.

B4
69. (amended) A method for identifying a molecule useful for the treatment of cancer comprising carrying out the method of claim 51, further comprising the step of administering the molecule to a non-human animal, and determining whether the molecule alters tumor progression in the treated animal.

SUB
D5
70. (amended) A method for identifying a molecule useful for the treatment of an infectious disease comprising carrying out the method of claim 51, further comprising the step of administering the molecule to a non-human animal, and determining whether the molecule ameliorates the infectious disease in the treated animal.

71. (amended) A method for identifying a molecule useful for the treatment of an autoimmune disease comprising carrying out the method of claim 51, further comprising the step of administering the molecule to a non-human animal, and determining whether the molecule ameliorates the autoimmune disease in the treated animal.

Add new claims 74-78, as follows:

74. (new) A method for identifying a molecule useful for the treatment of cancer comprising carrying out the method of claim 52, further comprising the step of administering the molecule to a non-human animal, and determining whether the molecule alters tumor progression in the treated animal.

B
75. (new) A method for identifying a molecule useful for the treatment of an infectious disease comprising carrying out the method of claim 52, further comprising the step of administering the molecule to a non-human animal, and determining whether the molecule ameliorates the infectious disease in the treated animal.

76. (new) A method for identifying a molecule useful for the treatment of an autoimmune disease comprising carrying out the method of claim 52, further comprising the step of administering the molecule to a non-human animal, and determining whether the molecule ameliorates the autoimmune disease in the treated animal.

SUB
D6
77. (new) The method of claim 51, 52, 69, 70, 71, 74, 75, or 76, wherein the heat shock